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Background
We have previously designed two polyepitope immuno-
gens, TBI and TCI, to stimulate the humoral and cellular
immune responses to HIV-1. Both immunogens were
included into virus-liked particles based vaccine named
CombiHIVvac. The goal of our study is analysis of Com-
biHIVvac immunogenic and toxic properties.
Methods
BALB/c (H-2 d) mice, 6 weeks of age were used for immu-
nization that was carried out twice (1 and 28 days) by
intramuscularly injection. One dose of the vaccine (0.2
ml/vol) contains 75 μg of DNApcDNA-TCI and 50 μg of
TBI. Blood samples were collected on days 7, 14, 28, 35,
42 and 62 from the on-start of immunization and assayed
by ELISA. Splenocyte samples were collected on day 35 for
ELISPOT.
Results
Immunization with CombiHIVvac gave rise to HIV-1 spe-
cific antibodies in the treated mice. The highest titer of the
antibodies as observed on day 35. The specificity of the
sera was evaluated by immunoblotting, the antibodies
specifically recognized the proteins of native HIV-1.
Immunization with CombiHIVvac triggers both CTL and
Th cells cloning. Single vaccine administration to mice in
a dose of 250 μg did not result in any significant variations
in body weight of experimental animals. The internal
organs of mice did not differ structurally from control ani-
mals. The vaccine had no appreciable effect on the hema-
tological parameters, except the 52% growth in blood
leukocyte counts that was reversible. Ten-fold administra-
tion of CombiHIVvac in doses of 5 μg or 50 μg did not
influence on the animal appearance, behavior or body
weight. There was no difference in the internal organs
weight indices between the experimental and control ani-
mals except spleen and lung weight.
Conclusion
CombiHIVvac does not cause long-term changes in phys-
iological, biochemical parameters in immunized animals
and it can be recommended for clinical trials.
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